A phase 2 trial investigating the efficacy and safety of the mPGES-1 inhibitor vipoglanstat in systemic sclerosis-related Raynaud's.
Göran TornlingCharlotte EdeniusJohn D PaulingChristopher P DentonAnna OlssonJan KowalskiAndrea MurrayMarina AndersonSmita BhatFrancesco Del GaldoFrances HallMariusz KorkoszDorota KrasowskaJacek OlasVanessa SmithJacob M van LaarMadelon C VonkAnna WojteczekAriane L HerrickPublished in: Rheumatology (Oxford, England) (2024)
Although vipoglanstat was safe, and well tolerated in a dose achieving full inhibition of mPGES-1, it was ineffective in SSc-related RP. Further development and evaluation of vipoglanstat will therefore be in other diseases where mPGES-1 plays a pathogenetic role.